Drug Search Results
More Filters [+]

ACTR-707

Alternative Names: actr-707, actr707, actr 707
Latest Update: 2021-10-11
Latest Update Note: Clinical Trial Update

Product Description

ACTR707 is derived from Unums novel proprietary Antibody-Coupled T cell Receptor (ACTR) platform.

Mechanisms of Action: CD28 Binder

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Cogent Biosciences
Company Location: CAMBRIDGE MA 02140
Company CEO: Andrew Robbins
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for ACTR-707

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ATTCK-20-03

P1

Terminated

Lymphoma

2020-09-21

42%

Recent News Events